CytRx Corporation Doses First Patient In Phase 2 Clinical Trial With Aldoxorubicin For The Treatment Of Unresectable Glioblastoma Multiforme (Brain Cancer)
Published: Jan 14, 2014
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that the first patient has been dosed in the Company’s Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer. The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide.
Help employers find you! Check out all the jobs and post your resume.